Janssen Inc. v. Teva Canada Ltd., 2022 FC 269 (Paliperidone*)
Justice Manson - 2022-02-25
Read full decision. Automatically generated summary:
This decision deals with the quantum of costs that were awarded to the Plaintiffs, Janssen Inc. and Janssen Pharmaceutica N.V., in this Court’s Judgment and Reasons in Janssen Inc. v. Teva Canada Ltd., 2020 FC 593, dated May 5, 2020 [the “Judgment”]. ... Given the above and having reviewed the Parties’ breakdown of fees for the course of this proceeding, I find the Plaintiffs’ reasonable legal fees are 70 percent of the actual fees claimed, namely $5,239,214.91, reduced from the claimed amount of $7,484,592.73, of which 35 percent is $1,833,725.22, which includes any sales taxes. ... Given the above, I find that the Plaintiffs’ reasonable disbursements are 80% of the claimed amount, namely $863,946.57, reduced from $1,079,933.21.
Decision relates to:
- T-353-18 - JANSSEN INC. ET AL v. TEVA CANADA LIMITED